While Moderna is testing Omicron-specific boosters for this fall, its investor Flagship Pioneering is building a biotech that says it uses AI to predict virus variants prior to outbreaks.Apriori Bio, derived from the Latin phrase a priori that translates to “from the previous,” emerged from stealth Monday with $50 million. The Cambridge, MA-based biotech was founded in 2020 in the midst of the Covid-19 pandemic, though Apriori CEO Lovisa Afzelius says the biotech will tackle multiple “ultra-dynamic” viruses outside of SARS-CoV-2, including the flu virus and HIV.<a href="https://endpts.com/flagship-unwraps-new-ai-biotech-that-looks-to-predict-variants-before-theyre-here/">Read more</a>

Endpoints News: Flagship unwraps new AI biotech that looks to predict variants before they’re here